These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34505178)

  • 41. Rates of osteoporosis screening and treatment following vertebral fracture.
    Barton DW; Behrend CJ; Carmouche JJ
    Spine J; 2019 Mar; 19(3):411-417. PubMed ID: 30142455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.
    Moriwaki K; Noto S
    Osteoporos Int; 2017 Feb; 28(2):621-632. PubMed ID: 27699441
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vertebral fractures cascade: potential causes and risk factors.
    Che H; Breuil V; Cortet B; Paccou J; Thomas T; Chapuis L; Debiais F; Mehsen-Cetre N; Javier RM; Loiseau Peres S; Roux C; Briot K
    Osteoporos Int; 2019 Mar; 30(3):555-563. PubMed ID: 30519756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment.
    King AB; Saag KG; Burge RT; Pisu M; Goel N
    Osteoporos Int; 2005 Dec; 16(12):1545-57. PubMed ID: 15942702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces.
    Crilly RG; Kloseck M; Chesworth B; Mequanint S; Sadowski E; Gilliland J
    Osteoporos Int; 2014 Jan; 25(1):205-10. PubMed ID: 23907572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medical Costs for Osteoporosis-Related Fractures in High-Risk Medicare Beneficiaries.
    Kapinos KA; Fischer SH; Mulcahy A; Hayden O; Barron R
    J Am Geriatr Soc; 2018 Dec; 66(12):2298-2304. PubMed ID: 30289961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Effectiveness of a Private Orthopaedic Practice-Based Osteoporosis Management Service to Reduce the Risk of Subsequent Fractures.
    Sietsema DL; Araujo AB; Wang L; Boytsov NN; Pandya SA; Haynes VS; Faries DE; Taylor KA; Baser O; Jones CB
    J Bone Joint Surg Am; 2018 Nov; 100(21):1819-1828. PubMed ID: 30399076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Racial Disparities Exist in Outcomes After Major Fragility Fractures.
    Wright NC; Chen L; Saag KG; Brown CJ; Shikany JM; Curtis JR
    J Am Geriatr Soc; 2020 Aug; 68(8):1803-1810. PubMed ID: 32337717
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence and costs of osteoporotic patients with subsequent non-vertebral fractures in the US.
    Pike CT; Birnbaum HG; Schiller M; Swallow E; Burge RT; Edgell ET
    Osteoporos Int; 2011 Oct; 22(10):2611-21. PubMed ID: 21107532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.
    Cadarette SM; Solomon DH; Katz JN; Patrick AR; Brookhart MA
    Osteoporos Int; 2011 Mar; 22(3):943-54. PubMed ID: 20532481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
    Stevenson M; Davis S; Lloyd-Jones M; Beverley C
    Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost and management of males with closed fractures.
    Brenneman SK; Yurgin N; Fan Y
    Osteoporos Int; 2013 Mar; 24(3):825-33. PubMed ID: 22776864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
    Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
    Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.
    McClung MR; Williams GC; Hattersley G; Fitzpatrick LA; Wang Y; Miller PD
    Calcif Tissue Int; 2018 Jun; 102(6):627-633. PubMed ID: 29285549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
    Pongchaiyakul C; Nanagara R; Songpatanasilp T; Unnanuntana A
    J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
    [No Abstract]   [Full Text] [Related]  

  • 57. Economic burden of osteoporotic fractures in US managed care enrollees.
    Williams SA; Chastek B; Sundquist K; Barrera-Sierra S; Leader D; Weiss RJ; Wang Y; Curtis JR
    Am J Manag Care; 2020 May; 26(5):e142-e149. PubMed ID: 32436682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.
    Scotland G; Waugh N; Royle P; McNamee P; Henderson R; Hollick R
    Pharmacoeconomics; 2011 Nov; 29(11):951-61. PubMed ID: 21854080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.
    Borgström F; Ström O; Kleman M; McCloskey E; Johansson H; Odén A; Kanis JA
    Osteoporos Int; 2011 Mar; 22(3):955-65. PubMed ID: 20532482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.